Maheshwari Arvind, Nippoldt Todd, Davidge-Pitts Caroline
Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA.
J Endocr Soc. 2021 Apr 16;5(9):bvab068. doi: 10.1210/jendso/bvab068. eCollection 2021 Sep 1.
Nonsuppressed levels of testosterone are seen in up to a quarter of transgender women on gender-affirming feminizing hormonal treatment. Multiple factors contribute to this situation, including patient, medication, laboratory, and organ-specific concerns. We propose a stepwise approach to determine the etiology of nonsuppressed levels of testosterone in transgender women. This may lead to an appropriate feminizing hormonal therapy regimen and diagnosis of manageable medical conditions.
在接受性别肯定性女性化激素治疗的跨性别女性中，高达四分之一的人睾酮水平未得到抑制。多种因素导致了这种情况，包括患者、药物、实验室和器官特异性问题。我们提出一种逐步的方法来确定跨性别女性睾酮水平未得到抑制的病因。这可能会带来合适的女性化激素治疗方案，并诊断出可控制的医学状况。
